At the news
? NEUTRALIMPACT 3/10 SC 13G/A filed Nov 9, 2026 at 16:30 ET
Soleus Capital Master Fund, L.P. filed an amended Schedule 13G disclosing a 8.6% passive stake in Palisade Bio, Inc., holding 14,996,154 shares as of September 30, 2026. This is an increase from the prior filing by Vanguard (5.16%) and from Soleus's own prior filing (not provided in detail), indicating continued accumulation by a hedge fund manager. The filing remains passive (Rule 13d-1(c)), with no activist intent signaled.
- Soleus Capital Master Fund, L.P. holds 14,996,154 shares of Palisade Bio common stock, representing 8.6% of shares outstanding as of September 30, 2026.
- The percentage is based on 174,270,558 shares outstanding as of August 6, 2026 (per the issuer's Form 10-Q).
- The filing is an amendment to Schedule 13G, indicating a passive investment under Rule 13d-1(c).
- Soleus Capital, LLC is the general partner; Soleus Capital Group, LLC is the managing member; Soleus Capital Management, L.P. is the investment manager; Guy Levy is the sole managing member of the relevant entities.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access